In Re Diet Drugs (Phentermine/Fenfluramine/Dexfenfluramine) Products Liability Litigation

551 F. App'x 642
CourtCourt of Appeals for the Third Circuit
DecidedJanuary 6, 2014
Docket12-4491
StatusUnpublished

This text of 551 F. App'x 642 (In Re Diet Drugs (Phentermine/Fenfluramine/Dexfenfluramine) Products Liability Litigation) is published on Counsel Stack Legal Research, covering Court of Appeals for the Third Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re Diet Drugs (Phentermine/Fenfluramine/Dexfenfluramine) Products Liability Litigation, 551 F. App'x 642 (3d Cir. 2014).

Opinion

OPINION OF THE COURT

JORDAN, Circuit Judge.

Sydney Davis appeals an order of the United States District Court for the Eastern District of Pennsylvania denying her recovery under the terms of the Diet Drug Nationwide Class Action Settlement Agreement (“Settlement Agreement”). We will affirm.

I. Background

This appeal relates to the settlement of multi-district products liability litigation regarding the diet drugs Pondimin and Redux, previously sold by American Home Products (“AHP”). See In re Diet Drugs Prods. Liab. Litig., 543 F.3d 179, 181 (3d Cir.2008). In November 1999, Wyeth, the successor-in-interest to AHP, joined plaintiffs’ representatives in the Settlement Agreement, which the District Court approved in August 2000. See id. at 181. Under the terms of the Settlement Agreement, Wyeth was required to contribute funds for the payment of claims. See id. at 180. The AHP Settlement Trust (the “Trust”), acting through its trustees and claims administrator, administers and reviews claims to determine the benefits, if any, that a class member is qualified to receive under the terms defined in the Settlement Agreement. See id. 1

Davis, a class member, sought compensation benefits under the Settlement Agreement. She based her claim on an echocardiogram performed in 2002 after she had ingested Pondimin for six months. Having reviewed the echocardiogram, her cardiologist, Dr. Mark Burton, diagnosed her with an ejection fraction of 60%. Under the Settlement Agreement, that percentage is the upper limit of what is considered a reduced ejection fraction— meaning that the heart does not optimally pump blood with each beat — and is one of the qualifying medical conditions for compensation benefits under the Settlement Agreement. 2 On one of her application forms, her attesting physician, Dr. Gregory Boxberger, confirmed that she had a reduced ejection fraction in the range of 50 to 60%. Upon review, the Trust’s auditing cardiologist concluded that there was no “reasonable medical basis” 3 for Dr. Boxberger’s finding that Davis suffered a reduced ejection fraction in that *644 range and instead determined the ejection fraction to be “qualitatively more than 65%.” (App. at A 1636.) Accordingly, the Trust denied Davis’s claim.

Davis, disagreeing with that determination, submitted a Notice of Contest of Post Audit Determination, pursuant to Audit Rule 18 of the Settlement Agreement. She attached a supplemental affidavit from Dr. Boxberger as well as affidavits from three additional cardiologists, all attesting that they had interpreted the echocardio-gram and agreed with Dr. Boxberger’s finding that she had an ejection fraction of 50-60%. After reviewing these additional materials and comparing them to the auditing cardiologist’s findings, the Trust reaffirmed its decision to deny Davis compensation benefits in a Final Post Audit Determination.

Davis formally disputed the Trust’s Final Post Audit Determination, and the Trust subsequently applied to the District Court to require Davis to show cause why her claim should be paid. The District Court issued a show-cause order to Davis and referred Davis’s claim to a Special Master, who in turn appointed a Technical Advisor to review Davis’s claim. The Technical Advisor issued a Technical Ad-visor Report, as required by the Settlement Agreement, on October 2, 2007. In the report, the Technical Advisor agreed with the auditing cardiologist and con-eluded that there was no reasonable medical basis for Dr. Boxberger’s finding of a reduced ejection fraction. The show-cause record, including that report and the parties’ statements of the case, was then submitted to the District Court. After reviewing the record, the District Court determined that Davis had failed to meet her burden of proving that a reasonable medical basis existed to support her claim. The District Court thus affirmed the Trust’s denial of her claim. Davis timely appealed.

II. Discussion 4

On appeal, Davis contends that the District Court erred in improperly relying on the opinion of the Technical Advisor to affirm the Trust’s denial of her claim 5 and in determining that she had failed to meet her burden of demonstrating a reasonable medical basis for the attesting physician’s finding of a reduced ejection fraction. We disagree with both of those contentions.

The Settlement Agreement Audit Rules permit a Special Master to assign a Technical Advisor to review the record and to prepare a report to the District Court “setting forth his/her opinions regarding the issue(s) in dispute in the audit.” (App. at 1524.) The Technical Advisor also “act[s] as a sounding board for the judge— helping the jurist to educate himself in the jargon and theory disclosed by the testi *645 mony and to think through the critical technical problems.” Reilly v. United States, 863 F.2d 149, 158 (1st Cir.1988). A review of the District Court’s Memorandum Opinion and the show-cause record demonstrates that the Court carefully considered the entire record, not just what the Technical Advisor said. Nothing here indicates a simple “rubber stamping” of the Technical Advisor’s opinion. 6 (Appellant’s Opening Br. at 12; App. at A3-A 13.)

The District Court’s determination was also not clearly erroneous. “The test is not what this court would have done under the same circumstances; that is not enough. The Court must feel that only one order could have been entered on the facts.” In re Orthopedic Bone Screw Prods. Liab. Litig., 246 F.3d 315, 320 (3d Cir.2001) (quotation marks omitted) (quoting In re Gypsum Antitrust Cases, 565 F.2d 1123, 1128 (9th Cir.1977)). Davis fails to show that the only conclusion that could be drawn from her echocardiogram is that she suffered from a reduced ejection fraction. As the District Court noted, she failed to rebut the opinions of the auditing cardiologist and the Technical Ad-visor that she did not have a reduced ejection fraction. She merely stood on her own cardiologists’ affirmations, which only disagree with those findings. But disagreement, without more, does not foreclose contrary conclusions. Because Davis cannot demonstrate that the District Court’s determination was clearly erroneous, her argument that she met her burden to show a reasonable medical basis for her condition must fail. 7

III. Conclusion

For the foregoing reasons, we will affirm.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
551 F. App'x 642, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-diet-drugs-phenterminefenfluraminedexfenfluramine-products-ca3-2014.